Find a Clinical Trial

MLS-101-206

A PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LORUNDROSTAT ALONE, AND LORUNDOSTAT IN COMBINATION WITH DAPAGLIFLOZIN, IN ADULTS WITH HYPERTENSION AND CHRONIC KIDNEY DISEASE WITH ALBUMINURIA

18-100

Learn more

Allogenic Hepatocyte Transplantation into Periduodenal Lymph Nodes

A Phase 2a, Open Label, Dose Escalation Study for Safety, Tolerability, and Efficacy of Hepatocyte Transplantation Into Periduodenal Lymph Nodes Among Subjects With End-Stage Liver Disease

18-70

Learn more

TAP Block and minimally invasive hysterectomy for pain control

A randomized, controlled, observer-blinded pilot trial of laparoscopic large volume, multisite transversus abdominal plane (TAP) block with liposomal bupivacaine in patients undergoing minimally invasive hysterectomy for endometrial cancer

18-80

Learn more

Multi-spectral imaging

Label-free, multi-scale imaging for improved detection of ovarian cancer metastases

18-99

Learn more

Non- Invasive, Label-free Detection of Cervical Pre-Cancers In vivo

Non-Invasive, Label-free Detection of Cervical Pre-Cancers In vivo

18-100

Learn more

The Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C)

The Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C)

18-70

Learn more

Voyage Study

VK2809 A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Assess The Efficacy, Safety, And Tolerability Of VK2809 Administered For 52 Weeks Followed By A 4-Week Off-Drug Phase In Subjects With Biopsy Proven Non-Alcoholic Steatohepatitis With Fibrosis

18-75

Learn more

Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma (XPORT-EC-042)

XPORT-EC-042 (GOG-3083): A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

18+

Learn more